BACKGROUND: The catecholamine release-inhibitor catestatin and its precursor chromogranin A (CHGA) may constitute "intermediate phenotypes" in the analysis of genetic risk for cardiovascular disease such as hypertension. Previously, the vacuolar H(+)-ATPase subunit gene ATP6V0A1 was found within the confidence interval for linkage with catestatin secretion in a genome-wide study, and its 3'-UTR polymorphism T+3246C (rs938671) was associated with both catestatin processing from CHGA and population blood pressure. We explored the molecular mechanism of this effect by experiments with transfected chimeric photoproteins in chromaffin cells. METHODS AND RESULTS: Placing the ATP6V0A1 3'-UTR downstream of a luciferase reporter, we found that the C (variant) allele decreased overall gene expression. The 3'-UTR effect was verified by coupled in vitro transcription/translation of the entire/intact human ATP6V0A1 mRNA. Chromaffin granule pH, monitored by fluorescence of CHGA/EGFP chimera during vesicular H(+)-ATPase inhibition by bafilomycin A1, was more easily perturbed during coexpression of the ATP6V0A1 3'-UTR C-allele than the T-allele. After bafilomycin A1 treatment, the ratio of CHGA precursor to its catestatin fragments in PC12 cells was substantially diminished, though the qualitative composition of such fragments was not affected (on immunoblot or matrix-assisted laser desorption ionization (MALDI) mass spectrometry). Bafilomycin A1 treatment also decreased exocytotic secretion from the regulated pathway, monitored by a CHGA chimera tagged with embryonic alkaline phosphatase. 3'-UTR T+3246C created a binding motif for micro-RNA hsa-miR-637; cotransfection of hsa-miR-637 precursor or antagomir/inhibitor oligonucleotides yielded the predicted changes in expression of luciferase reporter/ATP6V0A1-3'-UTR plasmids varying at T+3246C. CONCLUSIONS: The results suggest a series of events whereby ATP6V0A1 3'-UTR variant T+3246C functioned: ATP6V0A1 expression probably was affected through differential micro-RNA effects, altering vacuolar pH and consequently CHGA processing and exocytotic secretion.
BACKGROUND: The catecholamine release-inhibitor catestatin and its precursor chromogranin A (CHGA) may constitute "intermediate phenotypes" in the analysis of genetic risk for cardiovascular disease such as hypertension. Previously, the vacuolar H(+)-ATPase subunit gene ATP6V0A1 was found within the confidence interval for linkage with catestatin secretion in a genome-wide study, and its 3'-UTR polymorphism T+3246C (rs938671) was associated with both catestatin processing from CHGA and population blood pressure. We explored the molecular mechanism of this effect by experiments with transfected chimeric photoproteins in chromaffin cells. METHODS AND RESULTS: Placing the ATP6V0A1 3'-UTR downstream of a luciferase reporter, we found that the C (variant) allele decreased overall gene expression. The 3'-UTR effect was verified by coupled in vitro transcription/translation of the entire/intact humanATP6V0A1 mRNA. Chromaffin granule pH, monitored by fluorescence of CHGA/EGFP chimera during vesicular H(+)-ATPase inhibition by bafilomycin A1, was more easily perturbed during coexpression of the ATP6V0A1 3'-UTR C-allele than the T-allele. After bafilomycin A1 treatment, the ratio of CHGA precursor to its catestatin fragments in PC12 cells was substantially diminished, though the qualitative composition of such fragments was not affected (on immunoblot or matrix-assisted laser desorption ionization (MALDI) mass spectrometry). Bafilomycin A1 treatment also decreased exocytotic secretion from the regulated pathway, monitored by a CHGA chimera tagged with embryonic alkaline phosphatase. 3'-UTR T+3246C created a binding motif for micro-RNA hsa-miR-637; cotransfection of hsa-miR-637 precursor or antagomir/inhibitor oligonucleotides yielded the predicted changes in expression of luciferase reporter/ATP6V0A1-3'-UTR plasmids varying at T+3246C. CONCLUSIONS: The results suggest a series of events whereby ATP6V0A1 3'-UTR variant T+3246C functioned: ATP6V0A1 expression probably was affected through differential micro-RNA effects, altering vacuolar pH and consequently CHGA processing and exocytotic secretion.
Authors: A N Smith; J Skaug; K A Choate; A Nayir; A Bakkaloglu; S Ozen; S A Hulton; S A Sanjad; E A Al-Sabban; R P Lifton; S W Scherer; F E Karet Journal: Nat Genet Date: 2000-09 Impact factor: 38.330
Authors: Daniel T O'Connor; Mala T Kailasam; Brian P Kennedy; Michael G Ziegler; Noboru Yanaihara; Robert J Parmer Journal: J Hypertens Date: 2002-07 Impact factor: 4.844
Authors: Zhiyun Wei; Kuixing Zhang; Gen Wen; Karthika Balasubramanian; Pei-an B Shih; Fangwen Rao; Ryan S Friese; Jose P Miramontes-Gonzalez; Geert W Schmid-Schoenbein; Hyung-Suk Kim; Sushil K Mahata; Daniel T O'Connor Journal: J Hypertens Date: 2013-01 Impact factor: 4.844
Authors: Marc Santolini; Milagros C Romay; Clara L Yukhtman; Christoph D Rau; Shuxun Ren; Jeffrey J Saucerman; Jessica J Wang; James N Weiss; Yibin Wang; Aldons J Lusis; Alain Karma Journal: NPJ Syst Biol Appl Date: 2018-02-24
Authors: Setareh Orth-Alampour; Nathalie Gayrard; Silvia Salem; Àngel Argilés; Joachim Jankowski; Shruti Bhargava; Vera Jankowski; Bernard Jover; Cécile Notarnicola; Heidi Noels; Emiel P C van der Vorst; Christoph Kuppe; Michael Wolf; Claudia Goettsch; Wendy Theelen; Heike Bruck; Danilo Fliser; Joseph Loscalzo; Zhuojun Wu; Nikolaus Marx; Walter Zidek Journal: Basic Res Cardiol Date: 2021-10-13 Impact factor: 17.165
Authors: Megana K Prasad; Kavita Bhalla; Zhen Hua Pan; Jeffrey R O'Connell; Alan B Weder; Aravinda Chakravarti; Bin Tian; Yen-Pei C Chang Journal: PLoS One Date: 2013-10-01 Impact factor: 3.240
Authors: Charlotte Delay; Benjamin Grenier-Boley; Philippe Amouyel; Julie Dumont; Jean-Charles Lambert Journal: Alzheimers Res Ther Date: 2016-05-24 Impact factor: 6.982